ADORA1-driven metabolic reprogramming promotes therapy-induced senescence and chemoresistance, while senolytic or ADORA1-targeted interventions re-sensitise tumours to treatment.
nature.com/articles/s4138…
nature.com/articles/s4138…
@oncogenejournal